Loading
A phase 2 trial in lung cancer, run by Dana-Farber Cancer Institute, not yet recruiting.
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC is a phase 2, interventional study registered as NCT07551635 by Dana-Farber Cancer Institute, with a registry enrolment figure of 20 participants, started 2026-09-04 and due to reach its primary completion in 2028-01-31. Interventions recorded: FHD-286. Conditions listed: Small Cell Lung Cancer. Primary outcome: Objective Response Rate (ORR). Lung eligibility wording from the registry: "* Histologically or cytologically confirmed extensive stage SCLC with documented disease progression or recurrence after prior platinum-based therapy with or without checkpoint inhibitor". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.
Shares Lung cancer trials open today (registry snapshot), Small-cell lung cancer and the tag lung-deep-dive.